Aligos Discontinues Development of its Antisense Oligonucleotide Drug Candidate ALG-020572 in Subjects with Chronic Hepatitis B and Pivots Internal Strategic Emphasis to its Small Molecule Portfolio
Dosing in the first cohort discontinued after multiple reports of ALT flares suggestive of drug-induced…
FWD Group reports strong new business profitability growth
Chervon Names Thomas Scherer Vice President of Organizational Development – Sales, End User Marketing, and Service
Chervon Promotes Soobia Haroon to Vice President, Human Resources – NA
Chervon Names Jody Grimsley Senior National Account Manager
BIP Asia Forum and Entrepreneur Day set for November